Reneo Pharmaceuticals, Inc. (RPHM)

USD 18.2

(952.02%)

Annual Income Statements

(In USD)
Breakdown 2023 2022 2021 2020 2019
Revenue - - - - -
Cost of Revenue 525 Thousand 529 Thousand 50 Thousand 37 Thousand 34 Thousand
Gross Profit -525 Thousand -529 Thousand -50 Thousand -37 Thousand -34 Thousand
Operating Expenses 83.05 Million 53.84 Million 39.81 Million 19.55 Million 15.47 Million
Selling, General and Administrative Expenses 25.79 Million 16.14 Million 11.64 Million 3.6 Million 2.37 Million
Research and Development Expenses 56.61 Million 37.7 Million 28.16 Million 15.94 Million 13.09 Million
Other Expenses 650 Thousand 1.89 Million 48 Thousand 87 Thousand 3.03 Million
Cost and Expenses 83.05 Million 53.84 Million 39.81 Million 19.55 Million 15.47 Million
Operating Income -83.05 Million -53.84 Million -39.81 Million -19.55 Million -15.47 Million
Interest Expense - - - - -
Income Tax Expense 650 Thousand -1.89 Million -186.55 Thousand -169.29 Thousand -137.86 Thousand
Earnings before Tax -77.38 Million -51.95 Million -39.77 Million -19.46 Million -12.43 Million
Net Income -77.38 Million -50.06 Million -39.77 Million -19.46 Million -12.43 Million
Earnings Per Share Basic -25.23 -2.04 -2.19 -0.80 -1.60
Earnings Per Share Diluted -25.23 -2.04 -2.19 -0.80 -1.60
Weighted Average Shares Outstanding 3.06 Million 24.49 Million 18.14 Million 24.21 Million 7.78 Million
Weighted Average Shares Outstanding (Diluted) 3.06 Million 24.49 Million 18.14 Million 24.21 Million 7.78 Million
Gross Margin - - - - -
EBIT Margin - - - - -
Profit Margin - - - - -
EBITDA -82.23 Million -53.76 Million -39.76 Million -19.51 Million -15.43 Million
Earnings Before Tax Margin - - - - -

Income Statement Charts